Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 6, 2019
Aptevo Announces Proposed Public Offering of Common Stock and Warrants
SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced ...
February 26, 2019
Neovasc Announces Pricing of $5 Million Public Offering of Common Shares
VANCOUVER, Feb. 26, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten ...
February 26, 2019
RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
February 26, 2019
VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA)
TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating the potential of its VB-600 ...
February 26, 2019
Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company ...
February 26, 2019
Immutep to Present at Upcoming Industry Conferences
SYDNEY, Australia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments ...
February 26, 2019
electroCore Announces Positive Coverage Policies of gammaCore Issued by Highmark
BASKING RIDGE, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that Highmark, one of the nation’s ...
February 26, 2019
Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update
FLORHAM PARK, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
February 26, 2019
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today provided a corporate update and reported financial results for the fourth quarter and ...
February 26, 2019
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
DUBLIN, Feb. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (TBPH) today reported financial results for the fourth quarter and full year ...
February 26, 2019
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
LA JOLLA, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat ...
February 26, 2019
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results
MINNEAPOLIS, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative ...
February 21, 2019
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living ...
February 21, 2019
Genkyotex to Present Corporate Overview at Two Upcoming NASH Conferences
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that members of management ...
February 21, 2019
DURECT Corporation to Participate in the Berenberg NASH Day
CUPERTINO, Calif., Feb. 21, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will ...
February 21, 2019
Genocea to Host Quarterly Corporate Update Conference Call & Webcast on February 28 at 9:00 am ET
CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host ...
February 21, 2019
Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28
EMERYVILLE, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report ...
February 21, 2019
HTG Molecular to Present Corporate Overview at the Cowen & Company 39th Annual Health Care Conference
TUCSON, Ariz., Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, ...
February 21, 2019
CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28
NEWARK, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
February 21, 2019
Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
Page 29 of 158